PARP1 and acute lymphoblastic leukemia: Analyzing ALL p190+ patient samples, clear differential expression of PARP1 may be seen, as evidenced by the significant twofold increase compared with healthy donors (p < 0.01; Figure 8A), while statistical analysis of CML p190+ patient samples highlights repressed expression, evidenced by a 0.35-fold change when compared with healthy donors (p < 0.01; Figure 8B).